1. Home
  2. EROK vs ALT Comparison

EROK vs ALT Comparison

Compare EROK & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EagleRock Land LLC Class A shares representing limited liability company interests

EROK

EagleRock Land LLC Class A shares representing limited liability company interests

N/A

Current Price

$21.76

Market Cap

623.3M

Sector

Energy

ML Signal

N/A

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$2.67

Market Cap

573.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EROK
ALT
Founded
2023
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
623.3M
573.8M
IPO Year
2026
2005

Fundamental Metrics

Financial Performance
Metric
EROK
ALT
Price
$21.76
$2.67
Analyst Decision
Buy
Strong Buy
Analyst Count
6
10
Target Price
★ $28.83
$17.11
AVG Volume (30 Days)
152.7K
★ 3.0M
Earning Date
11-19-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 25.37
EPS
★ N/A
N/A
Revenue
N/A
★ $41,000.00
Revenue This Year
$154.84
N/A
Revenue Next Year
$17.21
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 105.00
52 Week Low
$20.06
$2.56
52 Week High
$27.42
$6.44

Technical Indicators

Market Signals
Indicator
EROK
ALT
Relative Strength Index (RSI) 40.27 29.36
Support Level $20.13 $2.57
Resistance Level $22.53 $3.35
Average True Range (ATR) 0.99 0.13
MACD -0.10 -0.07
Stochastic Oscillator 38.19 4.40

Price Performance

Historical Comparison
EROK
ALT

About EROK EagleRock Land LLC Class A shares representing limited liability company interests

EagleRock Land LLC is a surface-focused land management company, focused on providing access to land, resources, and infrastructure assets in the Permian Basin, including areas in Texas and New Mexico. Its assets support oil and natural gas development, as well as activities related to power generation, water infrastructure, and other industries. Through its land position and integrated infrastructure assets, the company generates revenue and royalties from completion and production-based activities, including surface damages, ROWs, easements, commercial water supply and produced water recycling, handling and disposal and other surface and subsurface related activities.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: